| Clopidogrel | stent, in all type of patients | vs aspirin | NS | - | - | NS | NS | NS | - | - | - | - | NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 1.52 [0.75 3.07] | p=1.00 | 0 | 2682 | 1 | REAL-LATE, ZEST-LATE, | | Cardiovascular death | no data | | MACE | no data | | Major bleeding | 2.97 [0.31 28.58] | p=1.00 | 0 | 2682 | 1 | REAL-LATE, ZEST-LATE, | | stroke (fatal and non fatal) | 2.23 [0.68 7.25] | p=1.00 | 0 | 2682 | 1 | REAL-LATE, ZEST-LATE, | | myocardial infarction (fatal and non fatal) | 1.41 [0.54 3.73] | p=1.00 | 0 | 2682 | 1 | REAL-LATE, ZEST-LATE, | | cardiovascular events | no data | | any bleedings | no data | | GUSTO severe/moderate bleeding | no data | | Cardiovascular death/MI/stent thrombosis | no data | | stent thrombosis | 1.24 [0.33 4.62] | p=1.00 | 0 | 2682 | 1 | REAL-LATE, ZEST-LATE, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| REAL-LATE, ZEST-LATE, 2010 | clopidogrel plus aspirin | aspirin alone | patients who had received drugeluting
stents and had been free of major adverse cardiac or cerebrovascular events
and major bleeding for a period of at least 12 months |
|
| Clopidogrel | stent, in all type of patients | vs normal-dose clopidogrel | NS | NS | - | - | - | NS | - | NS | NS | NS | NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.70 [0.26 1.84] | p=1.00 | 0 | 2214 | 1 | GRAVITAS, | | Cardiovascular death | 0.37 [0.10 1.41] | p=1.00 | 0 | 2214 | 1 | GRAVITAS, | | MACE | no data | | Major bleeding | no data | | stroke (fatal and non fatal) | no data | | myocardial infarction (fatal and non fatal) | 1.11 [0.58 2.10] | p=1.00 | 0 | 2214 | 1 | GRAVITAS, | | cardiovascular events | no data | | any bleedings | 1.17 [0.90 1.53] | p=1.00 | 0 | 2214 | 1 | GRAVITAS, | | GUSTO severe/moderate bleeding | 0.60 [0.31 1.14] | p=1.00 | 0 | 2187 | 1 | GRAVITAS, | | Cardiovascular death/MI/stent thrombosis | 1.01 [0.58 1.76] | p=1.00 | 0 | 2214 | 1 | GRAVITAS, | | stent thrombosis | 0.62 [0.20 1.91] | p=1.00 | 0 | 2214 | 1 | GRAVITAS, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| GRAVITAS, 2011 | High-dose clopidogrel (600-mg initial dose, 150 mg daily thereafter) | regular clopidogrel dose | patients receiving drug-eluting stents with high residual platelet activity (PRU>=230) on the regular clopidogrel dose (platelet-function tests with the VerifyNow assay 12 to 24 hours after PCI) |
|
